Zhu Z, He Y, Shi M, et al. - Researchers here prospectively examined the links between plasma osteopontin concentrations and adverse clinical results among ischemic stroke patients. A total of 3545 ischemic stroke patients were selected from the China Antihypertensive Trial in Acute Ischemic Stroke. In participants, baseline plasma osteopontin levels were recorded. The composite outcome of mortality and major disability (modified Rankin scale score ≥3) at 1 year post-ischemic stroke was assessed (primary outcome). Following multivariate adjustment, each standard deviation increase in log-transformed osteopontin was linked with odds ratios or hazard ratios of 1.20, 1.11, 1.29, and 1.15 for primary outcome, major disability, death, and the composite outcome of death and vascular events, respectively. Findings showed that elevated risks of adverse clinical outcomes at 1 year post-ischemic stroke were observed in relation to increased plasma osteopontin levels at baseline. This indicates a promising value of osteopontin as a prognostic biomarker for ischemic stroke.